Clinical trials: Healthy Japanese Volunteers
Healthy Volunteer
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
- Trial name
- NCT07514260
- Testing
- ABBV-295
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AbbVie
Healthy Volunteer
A Study of LY3009104(Baricitinib) for Healthy Subjects
To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.
- Trial name
- NCT01247350
- Testing
- LY3009104
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Atherosclerotic Cardiovascular Disease
A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men
The aim of this study is to look at how the study medicine works in the body and how it is removed from the body. We are testing the study medicine to make a medicine that can help people lower their cholesterol level.
- Trial name
- NCT05003440
- Testing
- NNC0385-0434
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
A Healthy Subject Study With Z-360 and Placebo
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (including food effect) of single and multiple doses of Z-360 in healthy Japanese subjects.
- Trial name
- NCT01776463
- Testing
- Z-360
- Where
- Japan
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Zeria Pharmaceutical
Healthy
Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers
The purpose of this study is to assess the pharmacokinetics of AZD6140 and its active metabolite, safety, tolerability of AZD6140 following single administration in healthy male Japanese volunteers.
- Trial name
- NCT01588626
- Testing
- AZD6140
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Healthy
Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males
The purpose of the study is to determine whether the HPMC capsule of D961H 40 mg is bioequivalent to gelatine capsules of D961H 40 mg after a steady state is reached on Day 5
- Trial name
- NCT00930215
- Testing
- D961H
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.
The primary aim of this study is to investigate the safety and tolerabilty of AZD4017 when given as single oral ascending doses to Japanese healthy male volunters. This will be done by comparing the effect of AZD4017 to placebo.
- Trial name
- NCT00799747
- Testing
- AZD4017
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers
This study will evaluate the drug behavior and safety of a single dose of the 11 milligram tofacitinib (CP-690,550) modified-release formulation in 24 healthy volunteers when taken after eating a high fat meal (the effect of…
- Trial name
- NCT02084875
- Testing
- tofacitinib modified-release (MR) formulation
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
E2022 Patch Formulation Multiple Dose Study
This study is to evaluate the safety and tolerability of a E2022 16 mg tape when applied repeatedly for 17 days to healthy elderly Japanese male subjects, using E2022 placebo tape as the control.
- Trial name
- NCT01450839
- Testing
- E2022
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Healthy-volunteers
A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants
The purpose of the study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of rozanolixizumab in japanese, chinese and caucasian healthy-volunteer study participants.
- Trial name
- NCT03859219
- Testing
- Rozanolixizumab
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Healthy
A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects
This study will investigate the dose-proportionality of palbociclib pharmacokinetics in healthy subjects of Japanese descent. Approximately fourteen healthy Japanese subjects will receive four single doses of palbociclib…
- Trial name
- NCT02059330
- Testing
- Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bleeding
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
"This is a single-center, randomized, double-blind, and placebo-controlled trial designed to: 1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A (FXa)-inhibitor induced anticoagulation; and…
- Trial name
- NCT03310021
- Testing
- Andexanet alfa, Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Healthy Volunteer
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
- Trial name
- NCT07570147
- Testing
- ABBV-1451
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of BIIB104 in healthy Japanese and non-Japanese participants.
- Trial name
- NCT05148481
- Testing
- BIIB104
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Biogen
Pharmacodynamics Study
Study to Assess the Pharmacodynamics/Pharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects
The purpose of this study is to assess the pharmacodynamics (intragastric pH) after repeated oral administration of D961H 10 mg and omeprazole 10 mg in Japanese healthy male subjects who are classified by the genotype of CYP2C19…
- Trial name
- NCT01159145
- Testing
- D961H, Omeprazole
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cholestasis
Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers
This study will be the first to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single dose of 10 milligrams (mg) to 180 mg of GSK2330672 in Japanese healthy subjects.
- Trial name
- NCT02801981
- Testing
- GSK2230672
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
Basmisanil Positron Emission Tomography Study in Japanese Volunteers
This study will evaluate the relationship between basmisanil plasma concentrations and the occupancy of Gamma-Amino Butyric Acid A (GABAA) receptor subtypes containing an alpha5 (α5) subunit in healthy Japanese volunteers.
- Trial name
- NCT02534207
- Testing
- Basmisanil
- Where
- 4 sites in United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers
This is an open-label, parallel-group study to evaluate the PK, safety, and tolerability of two different dose regimens of BG00012 over a 24-hour period to adult Chinese, Japanese, and Caucasian healthy volunteers.
- Trial name
- 109HV108 (NCT01453426)
- Testing
- BG00012 Dose 1, BG00012 Dose 2
- Where
- 2 sites in Australia, China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Volunteer
Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of multiple ascending oral doses of AZD1236 given to healthy young subjects for 13 days and to evaluate the single-dose relative…
- Trial name
- NCT00767052
- Testing
- AZD1236
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca